Search Close


Unaudited Interim Results for the six month period to 31st October 2010

31st January 2011

Scancell Holdings plc, the developer of therapeutic cancer and infectious disease vaccines based on its patented Immunobody® platform, is pleased to announce the interim results for the six month period ended 31st October 2010.


  • Successful progression of SCIB1, Scancell's lead vaccine for melanoma, which entered clinical trials in June 2010

  • Raised £2.5 million in April 2010 with new and current shareholders

  • Moved from PLUS to AIM in July 2010

  • Secured licensing agreements with:

    • the National Institutes of Health (an agency of the United States Department of Health and Human Services); and

    • Cancer Research Technology Ltd (Cancer Research UK's commercialisation and development arm)

  • Entered strategic collaborations with:

    • ImmuneRegen BioSciences, Inc.®; and

    • immatics biotechnologies GmbH

Post-period Highlights:

    • Four patients recruited to date for the clinical trials

    • Approval obtained to open a fourth UK patient recruitment site and to expand the patient population in the Phase I part of the study, to include all patients with Stage III and Stage IV malignant melanoma

    • Escalation of the dose and recruitment of the next group of patients in SCIB1 trial approved by the Cohort Review Committee


For further information contact:

Scancell Holdings Plc
Professor Lindy Durrant
+ 44 (0)207 245 1100

Hansard Communications
Kirsty Corcoran/Adam Reynolds
+44 (0)207 245 1100

Zeus Capital - Nominated Adviser/Joint Broker
Ross Andrews/Tom Rowley
+ 44 (0)161 831 1512

Matrix Corporate Capital LLP - Joint Broker
Robert Naylor/Stephen Waterman

View the full results 

Webcasts, Interviews and Media Coverage

Scancell Holdings lays groundwork for pivotal year

A £3.9mln injection from the life sciences fund Vulpes will effectively bankroll the latest R&D

Tue, 20 Aug 2019 06:05:00

Scancell to begin UK arm of phase II skin cancer trial ‘immediately’

Discussions with US regulators have taken longer than expected, so Scancell will now focus its efforts on completing the UK arm of the trial before re-submitting its US application at a later date

Mon, 19 Aug 2019 06:46:00